Seres Historical Balance Sheet

MCRB Stock

USD 0.89 0.12 15.58%

Trend analysis of Seres Therapeutics balance sheet accounts such as Property Plant And Equipment Net of 138.9 M provides information on Seres Therapeutics' total assets, liabilities, and equity, which is the actual value of Seres Therapeutics to its prevalent stockholders. By breaking down trends over time using Seres Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Seres Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Seres Therapeutics is a good buy for the upcoming year.

Seres Therapeutics Inventory

31.13 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.

About Seres Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Seres Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Seres Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Seres Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Seres currently owns. An asset can also be divided into two categories, current and non-current.

Seres Therapeutics Balance Sheet Chart

At present, Seres Therapeutics' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 103.6 M, whereas Total Assets are forecasted to decline to about 225.8 M.

Total Assets Other Current Liab Total Current Liabilities Property Plant And Equipment Net Other Assets Long Term Debt Total

Add Fundamental

Total Assets

Total assets refers to the total amount of Seres Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Seres Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Seres Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Seres Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from Seres Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Seres Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.At present, Seres Therapeutics' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 103.6 M, whereas Total Assets are forecasted to decline to about 225.8 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	38.5M	105.0M	73.9M	77.6M
Total Assets	354.9M	348.8M	358.6M	225.8M

Other Current Liab Total Assets

Seres Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Liab	Current Deferred Revenue	Long Term Debt	Common Stock Total Equity	Non Current Liabilities Total	Other Stockholder Equity	Property Plant And Equipment Gross
Total Assets		0.67	0.79	0.42	0.65	-0.06	-0.77	0.74	0.85	0.71	0.47	0.66	0.9	0.75	0.49	0.73	0.94	0.82	0.59	0.7	0.49	0.54	0.8	0.68	0.76	0.59
Other Current Liab	0.67		0.88	-0.18	0.95	0.49	-0.9	0.64	0.68	0.91	0.74	0.51	0.4	0.91	0.36	0.87	0.46	0.9	0.93	0.45	0.06	0.84	0.9	0.85	0.87	0.9
Total Current Liabilities	0.79	0.88		-0.11	0.9	0.35	-0.98	0.67	0.76	0.9	0.79	0.55	0.58	0.97	0.6	0.95	0.64	0.97	0.88	0.74	0.44	0.88	0.97	0.92	0.96	0.88
Total Stockholder Equity	0.42	-0.18	-0.11		-0.27	-0.52	0.15	0.24	0.17	-0.16	-0.3	0.29	0.66	-0.14	0.01	-0.27	0.61	-0.03	-0.3	0.0	0.26	-0.36	-0.05	-0.33	-0.06	-0.31
Property Plant And Equipment Net	0.65	0.95	0.9	-0.27		0.62	-0.91	0.56	0.58	0.97	0.84	0.43	0.35	0.92	0.32	0.93	0.42	0.91	0.97	0.57	0.14	0.91	0.91	0.92	0.84	0.98
Net Debt	-0.06	0.49	0.35	-0.52	0.62		-0.4	-0.18	-0.24	0.6	0.67	0.09	-0.38	0.45	-0.11	0.41	-0.31	0.4	0.67	0.03	-0.26	0.65	0.43	0.44	0.34	0.69
Retained Earnings	-0.77	-0.9	-0.98	0.15	-0.91	-0.4		-0.62	-0.74	-0.92	-0.78	-0.63	-0.53	-0.98	-0.58	-0.95	-0.6	-0.98	-0.9	-0.72	-0.44	-0.9	-0.98	-0.92	-0.98	-0.89
Accounts Payable	0.74	0.64	0.67	0.24	0.56	-0.18	-0.62		0.75	0.5	0.19	0.24	0.71	0.56	0.54	0.58	0.71	0.62	0.41	0.64	0.36	0.31	0.6	0.52	0.6	0.43
Cash	0.85	0.68	0.76	0.17	0.58	-0.24	-0.74	0.75		0.59	0.42	0.55	0.79	0.72	0.55	0.74	0.82	0.74	0.55	0.57	0.41	0.53	0.72	0.7	0.74	0.51
Non Current Assets Total	0.71	0.91	0.9	-0.16	0.97	0.6	-0.92	0.5	0.59		0.86	0.57	0.43	0.94	0.31	0.93	0.5	0.93	0.96	0.59	0.2	0.92	0.94	0.92	0.87	0.97
Non Currrent Assets Other	0.47	0.74	0.79	-0.3	0.84	0.67	-0.78	0.19	0.42	0.86		0.38	0.23	0.85	0.19	0.82	0.31	0.78	0.92	0.34	0.07	0.94	0.81	0.82	0.74	0.92
Other Assets	0.66	0.51	0.55	0.29	0.43	0.09	-0.63	0.24	0.55	0.57	0.38		0.57	0.66	0.28	0.52	0.61	0.67	0.49	0.38	0.4	0.51	0.66	0.49	0.71	0.43
Cash And Short Term Investments	0.9	0.4	0.58	0.66	0.35	-0.38	-0.53	0.71	0.79	0.43	0.23	0.57		0.52	0.49	0.49	0.99	0.6	0.29	0.57	0.6	0.25	0.58	0.43	0.56	0.29
Common Stock Shares Outstanding	0.75	0.91	0.97	-0.14	0.92	0.45	-0.98	0.56	0.72	0.94	0.85	0.66	0.52		0.51	0.95	0.59	0.98	0.94	0.61	0.32	0.92	0.98	0.92	0.96	0.91
Other Current Assets	0.49	0.36	0.6	0.01	0.32	-0.11	-0.58	0.54	0.55	0.31	0.19	0.28	0.49	0.51		0.49	0.5	0.58	0.31	0.61	0.73	0.33	0.56	0.43	0.6	0.27
Total Liab	0.73	0.87	0.95	-0.27	0.93	0.41	-0.95	0.58	0.74	0.93	0.82	0.52	0.49	0.95	0.49		0.55	0.93	0.91	0.7	0.35	0.91	0.93	0.99	0.89	0.92
Total Current Assets	0.94	0.46	0.64	0.61	0.42	-0.31	-0.6	0.71	0.82	0.5	0.31	0.61	0.99	0.59	0.5	0.55		0.67	0.37	0.61	0.59	0.34	0.65	0.49	0.62	0.37
Common Stock	0.82	0.9	0.97	-0.03	0.91	0.4	-0.98	0.62	0.74	0.93	0.78	0.67	0.6	0.98	0.58	0.93	0.67		0.91	0.67	0.45	0.89	1.0	0.89	0.97	0.89
Short Long Term Debt Total	0.59	0.93	0.88	-0.3	0.97	0.67	-0.9	0.41	0.55	0.96	0.92	0.49	0.29	0.94	0.31	0.91	0.37	0.91		0.44	0.11	0.97	0.92	0.91	0.86	0.99
Other Liab	0.7	0.45	0.74	0.0	0.57	0.03	-0.72	0.64	0.57	0.59	0.34	0.38	0.57	0.61	0.61	0.7	0.61	0.67	0.44		0.71	0.49	0.66	0.65	0.67	0.51
Current Deferred Revenue	0.49	0.06	0.44	0.26	0.14	-0.26	-0.44	0.36	0.41	0.2	0.07	0.4	0.6	0.32	0.73	0.35	0.59	0.45	0.11	0.71		0.22	0.43	0.29	0.46	0.12
Long Term Debt	0.54	0.84	0.88	-0.36	0.91	0.65	-0.9	0.31	0.53	0.92	0.94	0.51	0.25	0.92	0.33	0.91	0.34	0.89	0.97	0.49	0.22		0.91	0.91	0.87	0.96
Common Stock Total Equity	0.8	0.9	0.97	-0.05	0.91	0.43	-0.98	0.6	0.72	0.94	0.81	0.66	0.58	0.98	0.56	0.93	0.65	1.0	0.92	0.66	0.43	0.91		0.9	0.97	0.9
Non Current Liabilities Total	0.68	0.85	0.92	-0.33	0.92	0.44	-0.92	0.52	0.7	0.92	0.82	0.49	0.43	0.92	0.43	0.99	0.49	0.89	0.91	0.65	0.29	0.91	0.9		0.84	0.92
Other Stockholder Equity	0.76	0.87	0.96	-0.06	0.84	0.34	-0.98	0.6	0.74	0.87	0.74	0.71	0.56	0.96	0.6	0.89	0.62	0.97	0.86	0.67	0.46	0.87	0.97	0.84		0.82
Property Plant And Equipment Gross	0.59	0.9	0.88	-0.31	0.98	0.69	-0.89	0.43	0.51	0.97	0.92	0.43	0.29	0.91	0.27	0.92	0.37	0.89	0.99	0.51	0.12	0.96	0.9	0.92	0.82

Click cells to compare fundamentals

Seres Therapeutics Account Relationship Matchups

Seres Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	132.4M	342.9M	354.9M	348.8M	358.6M	225.8M
Other Current Liab	10.9M	21.7M	38.5M	105.0M	73.9M	77.6M
Total Current Liabilities	46.0M	46.4M	82.3M	85.6M	98.7M	103.6M
Total Stockholder Equity	(48.3M)	174.8M	131.5M	10.8M	(44.9M)	(42.6M)
Property Plant And Equipment Net	30.9M	22.9M	36.1M	134.0M	132.3M	138.9M
Net Debt	(20.3M)	(75.3M)	(130.8M)	(440K)	86.0M	90.3M
Retained Earnings	(459.6M)	(548.8M)	(614.4M)	(864.5M)	(978.2M)	(929.3M)
Accounts Payable	4.9M	4.0M	13.7M	17.4M	3.6M	6.7M
Cash	65.1M	116.0M	180.0M	163.0M	128.0M	93.9M
Non Current Assets Total	32.3M	74.2M	51.2M	154.0M	183.2M	192.3M
Cash And Short Term Investments	94.8M	253.6M	290.7M	181.3M	128.0M	156.3M
Common Stock Shares Outstanding	56.6M	79.8M	91.7M	108.1M	128.0M	134.4M
Other Current Assets	33.3M	11.5M	25.8M	13.4M	9.1M	10.4M
Total Liab	180.8M	168.2M	223.4M	338.0M	403.5M	423.6M
Total Current Assets	100.2M	268.8M	303.6M	194.8M	175.4M	166.7M
Common Stock	70K	91K	92K	125K	135K	141.8K
Short Long Term Debt Total	44.8M	40.8M	49.2M	162.6M	213.9M	224.6M
Other Liab	94.4M	86.6M	98.5M	93.9M	108.0M	78.0M
Current Deferred Revenue	25.8M	22.6M	16.8M	4.3M	7.7M	13.6M
Common Stock Total Equity	70K	91K	92K	125K	143.8K	150.9K
Liabilities And Stockholders Equity	132.4M	342.9M	354.9M	348.8M	358.6M	245.7M
Non Current Liabilities Total	134.8M	121.8M	141.1M	252.4M	304.8M	320.0M
Other Stockholder Equity	411.3M	723.5M	745.8M	875.2M	933.2M	979.9M
Property Plant And Equipment Gross	30.9M	22.9M	36.1M	134.0M	183.4M	192.6M
Accumulated Other Comprehensive Income	(27.7M)	(47K)	(60K)	(12K)	(13.8K)	(14.5K)
Short Term Debt	4.5M	5.6M	13.2M	4.1M	13.4M	7.8M
Property Plant Equipment	19.5M	13.9M	36.1M	23.0M	26.4M	21.7M
Net Tangible Assets	(48.3M)	174.8M	131.5M	10.8M	9.7M	9.2M
Short Term Investments	113.9M	0.0	29.7M	137.6M	110.7M	18.3M
Retained Earnings Total Equity	(459.6M)	(548.8M)	(614.4M)	(864.5M)	(778.1M)	(739.2M)
Capital Surpluse	411.3M	723.5M	745.8M	875.2M	1.0B	552.2M
Non Current Liabilities Other	110.1M	97.1M	116.5M	201.8M	1.6M	1.5M
Capital Lease Obligations	20.1M	15.7M	24.6M	111.5M	112.4M	118.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:

How To Invest In Seres

Details

Is Seres Stock a good investment?

Details

What is Seres Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.

You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.40)

Revenue Per Share

0.871

Quarterly Revenue Growth

(0.93)

Return On Assets

(0.1)

Return On Equity

(15.56)

The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Seres Historical Balance Sheet

Seres Therapeutics Inventory

31.13 Million

About Seres Balance Sheet Analysis

Seres Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Seres Therapeutics balance sheet Correlations

Seres Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Seres Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock Total Equity	+ 1.0	Common Stock
Total Current Assets	+ 0.99	Cash And Short Term Investments
Non Current Liabilities Total	+ 0.99	Total Liab
Property Plant And Equipment Gross	+ 0.99	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Common Stock	+ 0.98	Common Stock Shares Outstanding

Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock Total Equity	- 0.98	Retained Earnings
Common Stock	- 0.98	Retained Earnings
Common Stock Shares Outstanding	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Current Liabilities
Total Liab	- 0.95	Retained Earnings